Results 111 to 120 of about 976,470 (170)

Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study. [PDF]

open access: yesBreast Cancer Res Treat
Tolosa P   +25 more
europepmc   +1 more source

[Research trends on botulinum toxin A in bruxism: a bibliometric analysis]. [PDF]

open access: yesRev Med Inst Mex Seguro Soc
Vargas-Echeverría SL   +2 more
europepmc   +1 more source

[Editorial of the XLV SEMFYC Congress]. [PDF]

open access: yesAten Primaria
Morales MDPC, González AIG, Rodero AC.
europepmc   +1 more source

[Infectious tenosynovitis as an unusual focus of septic shock: A case report]. [PDF]

open access: yesAten Primaria
Mora-Aznar M   +2 more
europepmc   +1 more source

[Communication as a health imperative]. [PDF]

open access: yesAten Primaria
Gonzalez Natal MN   +3 more
europepmc   +1 more source

[SEFAC's 25th anniversary: consolidating evidence, planning for the future]. [PDF]

open access: yesFarm Comunitarios
Spanish Society of Community Pharmacy Research (SEFAC).
europepmc   +1 more source

Home - About - Disclaimer - Privacy